Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
Open Access
- 18 June 2018
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 36 (26), 3794-3801
- https://doi.org/10.1016/j.vaccine.2018.05.038
Abstract
No abstract availableKeywords
Funding Information
- Bill & Melinda Gates Foundation (OPP1115556)
- Bill & Melinda Gates Foundation (OPP1115556)
This publication has 33 references indexed in Scilit:
- Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines–A Randomized TrialPLOS ONE, 2013
- Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy AdultsPLOS ONE, 2011
- The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant VaccinesClinical and Vaccine Immunology, 2011
- Kinetics of the Natural, Humoral Immune Response toSalmonella entericaSerovar Typhi in Kathmandu, NepalClinical and Vaccine Immunology, 2009
- Bacteremic Typhoid Fever in Children in an Urban Slum, BangladeshEmerging Infectious Diseases, 2005
- Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese ChildrenInfection and Immunity, 2004
- Impact of age and drug resistance on mortality in typhoid fever.Archives of Disease in Childhood, 1996
- Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunizationVaccine, 1996
- LARGE-SCALE FIELD TRIAL OF TY21A LIVE ORAL TYPHOID VACCINE IN ENTERIC-COATED CAPSULE FORMULATIONThe Lancet, 1987